Cancer stem-like cells (CSCs)/cancerinitiating cells (CICs) are defined as a small population of cancer cells that have (1) high tumor-initiating ability, (2) selfrenewal ability and (3) differentiation ability (Fig. 1A) . 1 In recent studies, CSCs/CICs have shown to be resistant to cancer therapies by their senescence state, high expression of transporters to efflux anti-cancer drugs, high expression of apoptosis inhibitors, low expression of reactive oxygen species. 2 Thus, the action of CSCs/CICs are regarded as major mechanisms of cancer recurrence, distant metastasis and treatment resistance. However, effective cancer treatment targeting CSCs/CICs effectively have not been reported so far.
The prominent nature of the acquired immune system is its antigen specificity due to antigen-specific receptors including T cell receptors and B cell receptors, and isolation of human tumor-associated antigens (TAAs) has enabled us to target caner cells specifically in an antigen-specific manner. 3 Cancer immunotherapy trials using TAAs have recently been performed in several facilities and significant results have been obtained. 4 However, it is still not clear whether the immune system can recognize therapy-resistant CSCs/CICs or not. Some reports on immunity and CSCs/CICs have recently been published, and natural killer (NK) cells and cdT cells have been shown to recognize CSCs/ CICs derived from human colon cancer and gliomas; however CTLs, which are a major component of the acquired immune system, have not been characterized yet. 5 We analyzed the relation between CTLs and CSCs/CICs. 6 We isolated CSCs/CICs from human colon cancer cells using a side population (SP) technique. Since CTLs recognize antigenic peptides derived from TAAs, we evaluated the expression of TAAs in colon CSCs/CICs and nonCSCs/CICs. Colon CSCs/CICs expressed CEP55, one of the TAAs, at the same level as did non-CSCs/CICs. In a further study, we evaluated the expression of several TAAs in both CSCs/CICs and non-CSCs/CICs, and we found that the expression pattern can be classified into the following groups (Fig. 1B , unpublished data): (1) CSC/CIC antigens, which are expressed in CSCs/CICs but not in non-CSCs/CICs (e.g., MAGE-A3 and MAGE-A4); (2) shared antigens, which are expressed in both CSCs/CICs and non-CSCs/CICs (e.g., CEP55, SURVIVIN); and (3) non-CSC/CIC antigens, which are expressed in only non-CSCs/CICs but not in CSCs/CICs (e.g., AMACR, HIFPH3). Therefore, CEP55 is one of the (2) 9 and advanced cancer tissues may therefore contain more than 10 10 cancer cells. It is easy to imagine the difficulty in eliminating all cancer cells with such a limited number of CTLs (Estimated effector/target ratio is about 0.001 in the case of 10 7 CTL and 10 10 cancer cells.). On the other hand, if we focus on just CSCs/CICs targeting CSC/CIC antigens, the situation will be improved (Estimated effector/target ratio is about 0.1 in the case of 10 7 CTL, 10 10 cancer cells and 1% frequency of CSCs/CICs.). Therefore, targeting CSC/CIC antigens might be a more effective approach to eradicate higher tumorigenic CSCs/CICs and may bring about greater anti-tumor effects (Fig. 1C) .
As stated above, NK cells and cdT cells have been reported to recognize CSSs/ CICs. However, these immune cells belong to the innate immune system and do not recognize target cells in an antigenspecific manner. Thus, activation of these cells in vivo may not be more effective than CSC/CIC antigen-specific CTLs (Fig. 1C) . CTL adoptive transfer therapy has recently been described in detail, 10 and huge numbers of CTLs can be obtained by in vitro culture. Therefore, (2) shared antigens may also be suitable candidates for CTL adoptive transfer therapy using high numbers of CTLs.
In summary, CTLs can recognize CSCs/CICs as well as non-CSCs/CICs, and targeting CSC/CIC antigens with CTLs may be a reasonable approach for CSC/CIC targeting therapy.
